Arcus Biosciences SEC filings

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KOct. 23, 2026, 4:12 p.m. ETView on SEC.gov
Other events · Financial statements and exhibits
AI summary, unreviewedArcus Biosciences Prices $250 Million Share Offering at $17.50, Closes $269.7 Million Net Proceeds After Full Overallotment
424B5Oct. 22, 2026, 4:05 p.m. ETView on SEC.gov
424B5Oct. 21, 2026, 4:30 p.m. ETView on SEC.gov
8-KOct. 21, 2026, 4:09 p.m. ETView on SEC.gov
Results of operations and financial condition
AI summary, unreviewedArcus Biosciences Estimates $694.0 Million Cash and Marketable Securities as of September 30, 2026 in Preliminary, Unaudited Update
8-KOct. 20, 2026, 8:33 a.m. ETView on SEC.gov
Other events
AI summary, unreviewedArcus Biosciences Presents ARC-20 Casdatifan Data in Renal Cell Carcinoma, Reporting 50% First-Line cORR and 14.5-Month Second-Line Median PFS
4Aug. 24, 2026, 5:52 p.m. ETView on SEC.gov
SCHEDULE 13D/AAug. 7, 2026, 4:30 p.m. ETView on SEC.gov
10-QAug. 5, 2026, 4:11 p.m. ETView on SEC.gov
8-KAug. 5, 2026, 4:07 p.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits